EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

JAK Inhibitors Beyond Arthritis: Expanding Indications and Mechanisms of JAK Inhibitors in Rheumatology

Milan Bogojevic, Natasa Miketic, Elvira Strujic, Dragana Pravilovic Lutovac, Slavica Pavlov Dolijanovic, Lorenzo Dagna, Marco Matucci-Cerinic, Rifat Medjedovic, Milica Markovic

Journal of Clinical Medicine · 13.11.2026 · 15 (22) · 8894

DOI: 10.3390/jcm15228894 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 13.11.2026. Verfasst von Milan Bogojevic und 8 weiteren Autor:innen. Die Arbeit nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Clinical development of conventional JAK, selective TYK2, and dual TYK2/JAK1 inhibitors has expanded beyond inflammatory arthritis, but evidence across systemic rheumatic diseases varies substantially and the agents are not pharmacologically interchangeable. We conducted a structured narrative review of PubMed/MEDLINE and ClinicalTrials.gov with an initial search in May 2026 and targeted updates through 9 November 2026, prioritizing randomized trials and interpreting observational studies and case reports as exploratory. Findings were organized by the highest direct clinical evidence and the practical conclusions that evidence can support. Upadacitinib for giant cell arteritis and brepocitinib for adult dermatomyositis now have phase 3 evidence and regulatory approval in the United States; upadacitinib is also approved for giant cell arteritis in the European Union. In the 52-week VALOR trial, brepocitinib 30 mg improved mean Total Improvement Score versus placebo (46.5 vs. 31.2; p < 0.001), while serious infections were more frequent (10% vs. 1%). Evidence in systemic lupus erythematosus remains mixed, and phase 3 programs are ongoing. A randomized baricitinib trial in Sjögren disease has a promising conference-abstract result, but full peer-reviewed data are not yet available. Evidence in polymyalgia rheumatica, systemic sclerosis, other vasculitides, VEXAS, and monogenic inflammatory diseases remains less mature. Clinical use should follow disease-specific evidence, regulatory status, and individualized safety assessment; pathway plausibility alone does not establish efficacy or predict response.

Zitieren

APA

Bogojevic, M., Miketic, N., Strujic, E., Lutovac, D. P., Dolijanovic, S. P., Dagna, L., Matucci-Cerinic, M., Medjedovic, R., & Markovic, M. (2026). JAK Inhibitors Beyond Arthritis: Expanding Indications and Mechanisms of JAK Inhibitors in Rheumatology. Journal of Clinical Medicine, 15(22), 8894. https://doi.org/10.3390/jcm15228894

Vancouver

Bogojevic M, Miketic N, Strujic E, Lutovac DP, Dolijanovic SP, Dagna L, et al. JAK Inhibitors Beyond Arthritis: Expanding Indications and Mechanisms of JAK Inhibitors in Rheumatology. Journal of Clinical Medicine. 2026;15(22):8894. doi:10.3390/jcm15228894

BibTeX
@article{Bogojevic2026,
  author = {Bogojevic, Milan and Miketic, Natasa and Strujic, Elvira and Lutovac, Dragana Pravilovic and Dolijanovic, Slavica Pavlov and Dagna, Lorenzo and Matucci-Cerinic, Marco and Medjedovic, Rifat and Markovic, Milica},
  title = {JAK Inhibitors Beyond Arthritis: Expanding Indications and Mechanisms of JAK Inhibitors in Rheumatology},
  journal = {Journal of Clinical Medicine},
  year = {2026},
  volume = {15},
  number = {22},
  pages = {8894},
  doi = {10.3390/jcm15228894}
}
Kostenlos starten →